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Abstract. – Acute and chronic pain often re-
quires a multimodal approach. Combination
therapy reduces the number of individual daily
administrations and improves patient’s compli-
ance with the prescribed analgesic treatment.
Despite the association codeine/paracetamol is
one of the most widely used central analgesic,
the exact mechanism of action, particularly of
paracetamol, is still object of pharmacological
research. Recent findings showed that paraceta-
mol may act through cerebral cyclo-oxygenase,
descending opioidergic inhibitory pathways,
serotonin pathway, and the endocannabinoid
system; while codeine activity seems to related
not only to its conversion to morphine, as previ-
ously known, but also by itself and through its
metabolites, such as norcodeine (NORC) and
codeine-6-glucuronide (C-6-G). The addition of
codeine to paracetamol significantly improves
the analgesic action and reduces the number
needed to treat (NNT) from 5 to 2.3-3.1. Recent
warnings about the risk of its metabolism relat-
ed to CYP450 and its genetic variability in gener-
al population should be mainly considered when
the association is used in paediatric patients un-
dergoing tonsillectomy and/or adenoidectomy
procedures for obstructive sleep apnoea syn-
drome (OSAS). In adults, the association
codeine/paracetamol has been shown to be ef-
fective and safe in different settings: acute pain,
trauma patients, and chronic nociceptive pain.
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Introduction
Recent progresses on our knowledge of the
pathophysiological mechanisms underlying acute
pain and its evolution into chronic pain have
highlighted the need for analgesic treatments
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characterized by a multimodal approach, that si-
multaneously uses various methods to control
pain1,2.
More specifically, our understanding of the
mechanisms by which pain becomes chronic,
based primarily on the progress made in the field
of neuroplasticity3, have further confirmed the
need to use central analgesics, as an alternative to
the widely used non-steroidal anti-inflammatory
drugs (NSAIDs). The latter, in addition to being
burdened by a tolerability profile that makes
them incompatible with the majority of patients
requiring a prolonged antalgic treatment (elderly
subjects with a number of comorbidities, which
may increase their susceptibility to the cardiovas-
cular and gastrolesive effects of NSAIDs)4,5, act
primarily on peripheral cyclooxygenase and
therefore intervene only marginally in the man-
agement of chronic pain. Moreover, in accor-
dance with a number of guidelines, they may on-
ly be used for short periods, at the lowest effica-
cious dose and only in conditions of effective in-
flammatory exacerbation6,7.
Indeed, in the management of acute and
chronic pain, in addition to the use of multimodal
treatments based on the administration of various
drugs with different mechanisms of action, ad-
ministered in sequence according to specific regi-
mens, it is possible to plan therapies based on the
combined action of various compounds adminis-
tered in a single formulation, when the knowl-
edge of the pharmacokinetic characteristics and
the clinical effects of the different combined
drugs is complete.
The use of combination therapy brings a num-
ber of advantages: it reduces the number of indi-
vidual daily administrations and improves pa-
tient’s compliance with the prescribed analgesic
treatment.
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nociceptive neurotransmission in the dorsal horn
of the spinal cord19. The pharmacological profile
of 4-aminophenol is therefore identical to that
previously described for paracetamol, supporting
the hypothesis that the hepatic metabolite con-
tributes to the analgesic activity of paracetamol,
through the activation of the bulbospinal path-
ways19.
Another recent study showed how AM404
could also induce analgesia by inhibiting the T-
type calcium channels Ca(v)3.2, as occurs for
other lipoamino acids20.
The interaction with the endocannabinoid sys-
tem would therefore justify both the analgesic
and antipyretic effect of paracetamol. Moreover,
the consumption of AA, conjugated with p-AP to
form the metabolite AM404, reduces its avail-
ability for the production of inflammatory media-
tors, which explains why paracetamol reduces
the cerebral concentration of prostaglandins21.
With regard to the relationship between the
absorption of paracetamol and its analgesic ef-
fect, there are difficulties in interpreting the
analgesic and antipyretic responses observed af-
ter its administration, as these responses are not
directly related to plasma concentration, but
rather to those observed in the effect compart-
ment. Effect site concentration does not have re-
al measurable concentrations, however they are
roughly equivalent to those present in the cere-
brospinal fluid. Target effect compartment con-
centrations of 5 mg/l for fever and 10 mg/l for
pain do not seem unreasonable on the basis of
current literature22.
Therefore, although the time to reach thera-
peutic concentration in the effect site can reflect
that of plasma concentration, it is initially subject
to a delay, as its maximum concentration is lower
than the maximum plasma concentration after a
single dose. This delay, which can be quantified
as about 1 hour for paracetamol, depends on
body size, expressed in weight, and it is lower
the smaller the subject22.
In order to accelerate the onset of the effect,
the speed can be increased by administering a
higher first dose or by improving absorption
characteristics22. Absorption can be modified by
the formulation and in this sense an increase in
the rate of absorption would also increase the on-
set of the pharmacological action. Indeed, where-
as intravenous formulations go directly to the
central compartment, tablets and capsules have to
be disintegrated and then dissolved, thereby in-
troducing a delay even before duodenal absorp-
Paracetamol (or acetaminophen) is the most
commonly used agent in combination with opi-
oids (codeine, hydrocodone, tramadol, oxy-
codone)8-11 and of these, its combination with
codeine represents a milestone in acute and




Paracetamol, recently defined “a promising
ancestor”12, is an aniline derivative with anal-
gesic and antipyretic activity. The absence of a
peripheral action on prostaglandins makes the
compound better tolerated than NSAIDs, whose
side effects it does not share, especially the detri-
mental effect on the gastrointestinal mucosae and
the inhibition of platelet activity13.
Various hypotheses have been postulated by
different authors concerning its mechanism of
action, which is still not completely known: it
has been seen to have central actions on cerebral
cyclo-oxygenase14, on the descending opioidergic
inhibitory pathways and on the serotonin path-
ways15, inhibition of peroxydase but not cy-
clooxygenases, especially myeloperoxidase. This
latter mechanism is also thought to cause a re-
duction in the production of oxidants, which is
probably associated with inflammatory condi-
tions, such as atherosclerosis and rheumatic dis-
eases16.
It is likely that paracetamol exerts its analgesic
effect in a complex and multifactorial manner. As
highlighted recently, its analgesic activity is due
to an interaction with the endocannabinoid sys-
tem17. Paracetamol is metabolised, particularly in
the liver, to p-aminophenol (p-AP), a compound
that is subsequently conjugated with arachidonic
acid (AA) in cells containing fatty acid amide
hydrolase (FAAH) in the nervous system, includ-
ing Transient Receptor Potential Vanilloid, mem-
ber 1 (TRPV1)-expressing neurons: the effect of
this conjugation is the synthesis of N-arachi-
donoylaminophenol (AM404), a TRPV1 activa-
tor18. AM404, a metabolite of paracetamol, in-
hibits the enzyme that hydrolyses the endo-
cannabinoids (eCB), which prolongs the anal-
gesic action of the eCBs. AM404 therefore acti-
vates TRPV1 in the cerebral nuclei and this acti-
vation, through the stimulation of the descending
bulbospinal inhibitory pathways in the periaque-
ductal grey, can produce antinociception by regu-
lating the descending antinociceptive pathways,
possibly of serotoninergic origin, which reduces
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tion takes place. The orosoluble formulation has
the advantage of rapid disintegration and dissolu-
tion, which allows faster absorption than the nor-
mal oral formulations, therefore, guaranteeing a
faster onset of action23.
The absorption of paracetamol is also closely
related to the product’s particular dissociation ca-
pacity. Paracetamol has a pKa of 9.5 and, in the
alkaline duodenal environment, it is largely non-
ionised. Consequently, the absorption of the non-
ionised form from the duodenum into systemic
circulation is fast: the mean half-life (T½) for ab-
sorption is 6.8 minutes in adult volunteers). By
contrast, paracetamol absorption in the stomach
is minimal, and in this case the only limiting fac-
tor is the emptying of the stomach into the duo-
denum, and/or the presence of food, which can,
therefore slowdown absorption22.
Once it has been absorbed, 90% of paraceta-
mol is metabolised by glucuroconjugation or sul-
phation. In the liver paracetamol combines rapid-
ly with glutathione to form a non-toxic com-
pound that is eliminated in urine. In the event of
an overdose, if glutathione reserves are exhaust-
ed, the damage to the liver is not caused by the
paracetamol itself, but by the toxic metabolite N-
acetyl-p-benzoquinone imine (NAPQI)24.
To overcome this risk, in case of an overdose,
it is necessary to administer N-acetylcysteine, a
substance that restores the hepatic glutathione re-
serves. The use of N-acetylcysteine drastically
reduces hepatotoxicity, when administered 8-10
hours after an overdose. The suggested dose of
N-Acetylcysteine is 150 milligrams/kg over one
hour and subsequently 50 milligrams/kg over 4
hours15.
Paracetamol toxicity can be the consequence
of a single overdose or repeated excessive doses.
The maximum recommended therapeutic daily
dose for paracetamol is 4 g in adults (3 g in Italy,
for the oral formulation only), whereas a single
dose over 7.5 g is considered potentially toxic15.
As the use of analgesics is very common, even
small increases in the relative risk of renal dys-
function must be carefully evaluated. As previ-
ously published in literature, the study by
Rexrode25 provides reassuring evidence of an ap-
parent absence of a close relationship between
chronic use of analgesics and chronic renal dys-
function in a large cohort of subjects, in particu-
lar those without a prior history of renal insuffi-
ciency. The same conclusion was reached in an-
other, even more recent, study26, which showed
how the chronic use of paracetamol is not associ-
ated with renal insufficiency, even in subjects us-
ing the medicinal product for more than 30 days
from the time of monitoring or who have taken a
total annual dose of paracetamol greater than 1
kg (corresponding to a daily dose of 3 grams
maintained for the whole year).
As far as the risk of gastrointestinal bleeding is
concerned, the study by Lewis et al27 confirms
the safety of paracetamol. In the absence of non-
aspirin nonsteroidal anti-inflammatory drugs
(NANSAIDs), there was no evidence of any in-
crease in the risk of upper gastrointestinal tract
bleeding at any of the doses of paracetamol used.
Paracetamol, therefore, represents a safe alter-
native to NSAIDs28, also from the point of view
of cardiovascular risk, as confirmed by a study
enrolling a total of 2754 subjects treated with
paracetamol. Blood pressure was seen to increase
in a non-statistically significant way (systolic:
+1.6 mmHg, diastolic: +0.5 mmHg) during the
treatment with paracetamol in the group whose
antihypertensive treatment remained unchanged.
The authors concluded that they did not observe
any evidence able to confirm the hypothesis that
treatment with paracetamol caused a significant
rise in blood pressure in a population of patients
with treated hypertension29.
Paracetamol is usually recommended even
when analgesic drugs are required during oral
anticoagulant treatment (OAT), as it does not
have a significant effect on primary haemostasis:
the use of paracetamol during OAT, even for long
periods, did not cause any clinically-relevant
changes in INR30.
Finally, paracetamol is also considered the
preferred analgesic and antipyretic drug in the
paediatric setting, as it does not have any side ef-
fect typical of opioids31.
Looking Inside Codeine and
its Metabolites
Codeine is a weak opioid with a bioavailability
of approximately 30-40% after oral administra-
tion. To exert its analgesic activity, it must be
metabolised in part into morphine and its metabo-
lites (morphine-3-glucuronide and morphine-6-
glucuronide) and in part into the metabolites of
codeine: norcodeine (NORC) and codeine-6-
glucuronide (C-6-G). This process depends on the
activity of cytochromes CYP2D6 and CYP3A4,
belonging to the large CYP450 family.
In healthy volunteers codeine is metabolized
to C-6-G (81.0 ± 9.3%), NORC (2.16 ± 1.44%),
morphine (0.50 ± 0.39%), morphine-3-
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effects at a 45 mg dose administered to normal
metabolisers (that represent about 50% of the
Caucasian population).
The new safer and simpler diagnostic tech-
niques now available should allow a faster diag-
nosis of metabolic variations. Therefore, once the
patient’s genotype and phenotype is known, it
can be used as a kind of guideline to establish the
right dose of codeine, as the CYP genotype can
help to identify the best suited drug for the spe-
cific patient34.
Like all drugs that undergo direct CYP450-
mediated metabolism (among opioids: codeine,
tramadol, buprenorfine, oxycodone, fentanyl,
methadone), co-administration of codeine and
other medicinal products that induce or inhibit
CYP2D6 and CYP3A4 cytochromes can cause
pharmacological interactions and alter the re-
sponse to the drug36.
As far as the aforesaid genetic variability of
CYP2D6 is concerned, in October 2012 the Eu-
ropean Medicines Agency (EMA) launched a re-
view procedure for the benefit/risk profile of
products containing codeine, used for paediatric
pain relief37, following reports in literature, be-
tween 2009 and 2012, of three fatal cases of res-
piratory depression in children aged 2-5 years,
and ultrafast CYP2D6 metabolisers, who had
been administered codeine after a tonsillectomy
and/or adenoidectomy procedure to treat obstruc-
tive sleep apnoea syndrome (OSAS)38-39. Al-
though therapeutic doses were used, the combi-
nation of an ultrafast metaboliser profile and im-
paired respiratory condition (OSAS) proved deci-
sive, especially given the fact that in the immedi-
ate post-surgical period respiratory conditions
can momentarily worsen due to the procedure,
which involves the formation of oedema follow-
ing the removal of the tonsils/adenoids.
In July 2013, at the end of the review process,
the EMA confirmed the favourable benefit-risk
profile for codeine in children over 12 years of
age and recommended a number of measures to
guarantee a better safety profile for medicinal
products containing codeine, in particular the
contraindication for subjects under 12 years of
age and in patients from 0 to 18 years undergoing
tonsillectomy and/or adenoidectomy procedures
for OSAS and the recommendation not to use
codeine in children, aged between 12 and 18
years, with impaired respiratory function. Final-
ly, a limitation was introduced concerning the
number of days of therapy, which is particularly
necessary in those European countries in which
glucuronide (M-3-G) (2.10 ± 1.24%), morphine-
6-glucuronide (M-6-G) (0.80 ± 0.63%) and nor-
morphine (2.44 ± 2.42%)32.
The analgesic effect of codeine is equal to
about 1/10 of that induced by morphine, howev-
er, recent studies showed that codeine analgesia
depends, in addition to the morphine produced
by metabolisation through CYP2D6, also on
codeine itself and its metabolites, such as C-6-G
and NORC, which directly contribute to the anal-
gesia induced by the opioid33.
Lötsch et al32 analysed the extent of the contri-
bution to the analgesic effects of codeine and its
metabolites, regardless of the O-demethylation of
codeine to morphine, after having reported that
codeine has a half-life of 1.47 ± 0.32 hours, that
C-6-G has a half-life of 2.75 ± 0.79 hours and
that the plasma AUC of C-6-G is about ten times
greater than codeine. The authors concluded that
the CYP2D6-dependent formation of morphine
cannot fully explain the effects of codeine on the
central nervous system (CNS) and that C-6-G is
the most likely active fraction with a supplemen-
tary analgesic activity, with a possible contribu-
tion also by NORC.
Despite representing only 2-5% of all P450
liver enzymes, CYP2D6 is responsible for the
metabolism of 25% of all drugs used in clinical
practice: consequently, the polymorphism of this
cytochrome, which is responsible for the
metabolisation of codeine and formation of its
metabolites, can influence the analgesia induced
by this drug33.
The genetic variability in the expression of
these cytochromes means that patients can be
slow, medium, normal and ultrafast metabolisers,
with a significant variation in terms of analgesia
and side effects. About 10% of the Caucasian
population (one every ten treated patients) be-
longs to the slow metaboliser category and there-
fore, in these patients, codeine has a reduced
analgesic efficacy. Conversely, fast metabolisers
convert codeine rapidly into morphine and other
metabolites, and therefore they result more ex-
posed to the risk of side effects34.
The study by Kirchheiner et al35 on the phar-
macokinetics of codeine and of its metabolite
morphine, in ultrafast metabolisers, charac-
terised by a gene duplication encoded for
CYP2D6, showed a 1.5 × increase in exposure
to the morphine metabolite compared to normal
metabolisers: in other words, for an ultrafast
metaboliser (about 3% of the Caucasian popu-
lation) a 30 mg dose of codeine has the same
510
Plasma half-life (T½) Onset of analgesic activity Duration of analgesic activity
(min) (min) (h)
Paracetamol 150 15-30 6 (4-8)
Codeine 120-180 30 6 (4-8)
Table I. Pharmacokinetic parameters of paracetamol and codeine.
codeine combination products can be sold with-
out a medical prescription and dedicated above
all to the 12-18-year-old age group40. More
specifically, to avoid the risk of abuse, a condi-
tion has been imposed that analgesic drugs con-
taining codeine should not be taken for more
than three days without consulting a doctor. In
Italy, this would not happen as this type of drug
is available only on prescription and under the di-
rect control of a physician. The EMA’s recom-
mendations were subsequently assimilated by the
Member States, which updated the printed mate-
rials of medicinal products containing codeine
involved by the review.
Rationale for Codeine-Paracetamol
Association
The clinical rationale for an analgesic associa-
tion is based on the evidence that the analgesic
effect obtained is significantly superior to that
obtained by the single components, i.e., there
must be a synergistic action, with a significant
increase in “pain relief”.
In the case of the codeine-paracetamol combi-
nation, studies showed that the addition of codeine
to paracetamol causes a significant improvement
in the analgesic action, with an obvious and statis-
tically significant reduction in the number needed
to treat (NNT): from 5, the mean NNT reported
for paracetamol, to 2.3-3.1 for the codeine-parac-
etamol combination. In addition, this improvement
in the analgesic activity of paracetamol does not
affect its excellent tolerability41.
Combining different analgesics therefore be-
comes an important option in clinical practice,
because it is able both to control a greater num-
ber of pain components and to improve the toler-
ability of the drugs, which guarantees adequate
analgesic efficacy at lower doses than obtained
by the individual components. In the paraceta-
mol-codeine combination, the pharmacodynamic
parameters of the two drugs (Table I) are similar
and therefore their pharmacological action is
synchronous and has the same duration, thereby
guaranteeing maximum synergy.
Combining paracetamol with other analgesics,
in particular codeine, therefore finds its rationale
in the synergistic action of the two active sub-
stances, in order to boost the analgesic effect and
minimise the side effects, by reducing the dose of
the individual components. However, one point
that remains controversial is the optimum dose of
the two molecules when proposed in combina-
tion. As regards paracetamol alone, a linear rela-
tionship has been shown between the plasma
concentration and the dose administered per kilo-
gram of body weight and a dose of at least 15
mg/kg is needed to reach therapeutic levels of
paracetamol. The plasma concentration threshold
to be reached for an efficacious analgesic action
has been estimated at approximately 66 mol/L
and, therefore, the optimum dose in an adult with
an average weight of 60-70 kg is approximately
1.000 mg42.
In a recent randomized clinical study43 con-
ducted on over 500 patients in post-dental proce-
dural pain, the 1,000 mg dose of paracetamol
was statistically more efficacious than the 650
mg dose in pain management. Regarding side ef-
fects, there was no significant difference between
the two groups treated with paracetamol and
placebo. Even small differences in the posology
of paracetamol can therefore be decisive. Specifi-
cally, reducing the 1,000 mg dose of paraceta-
mol, when used alone, can cause a reduction in
analgesic efficacy.
As regards the optimum dose of paracetamol
in combination with codeine, taking into consid-
eration the synergic action, the 500 mg dose can
be considered the optimum adult dose, corre-
sponding to about 7 mg/kg. In the case of
codeine, on the other hand, in combination with
paracetamol, the optimum single dose has been
estimated to be 30 mg44. This combination there-
fore makes it possible to best exploit the syner-
gistic action of the two components, by using re-
duced doses to manage a level of pain that the in-
dividual drugs are unable to control alone.
A further reduction in the doses of paraceta-
mol in combination with other agents, as at pre-
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sent suggested in the United States (US), with
the recommendation to restrict combinations
with paracetamol to 325 mg45, can lead to a re-
duction in analgesic efficacy without any direct
benefit, apart from avoiding the overdoses that
can occur due to the inappropriate concomitant
use of multiple products containing paracetamol,
which is a very common practice in the US, giv-
en the very high availability of free-sale paraceta-
mol and the lack of clarity that characterises the
labelling of such drugs. In the US, accidental
overdoses are more common, as most over-the-
counter drugs also contain, amongst the various
compounds, paracetamol (medicines for coughs,
cystitis, pain of various origins, flu, fever, etc.). It
is therefore common for patients to combine self-
prescribed medicines containing paracetamol
with drugs prescribed by their general practition-
er, again containing paracetamol, without realis-
ing it, on account of unclear labels that often use
an abbreviation (i.e. APAP for acetaminophen) to
indicate the presence of this active ingredient.
Co-administration of different drugs containing
paracetamol can cause a hazardous accumulative
effect in the amount taken46. In January 2011, the
Food and Drug Administration (FDA) therefore
asked manufacturers to restrict to 325 mg the
dose of paracetamol present in the associations
containing opioids on prescription, within 3
years47. Most of the combinations containing
more than 325 mg of paracetamol were taken off
the market, however in 2014, upon reaching the
deadline, the FDA published a circular in which
it urged doctors to stop prescribing combination
drugs containing more than 325 mg of paraceta-
mol, until manufacturers had taken all non-com-
pliant products off the market48.
The situation in Europe is so different that the
EMA and Italian Medicines Agency (AIFA) did
not feel it necessary to adopt the same measures
for the European market.
The difference in the European and the Ameri-
can attitude to paracetamol was also highlighted
in a recent French survey on the knowledge and
correct application of the recommendations on
neuropathic pain, published in 2010 by the
French Society of Pain Research and Treatment
(Societè Francaise d’Etude et Traitement de la
Douleur, SFETD)49. More than 50% of the 319
French general practitioners who completed the
survey were aware of these recommendations
and in recognised cases of neuropathic pain, cor-
rectly managed the patient, according to the
guidelines of the SFETD. Moreover, in patients
with well diagnosed non-neuropathic pain, gen-
eral practitioners choose the codeine-paracetamol
combination in 77.7% of cases, which confirms
the usefulness of this combination for the treat-
ment of non-neuropathic pain.
Codeine-Paracetamol Association
in Clinical Practice
The combination of drugs belonging to differ-
ent classes (a non-anti-inflammatory central anal-
gesic and an opioid), therefore characterised by
different mechanisms of action, can offer the op-
portunity of optimising efficacy and tolerability,
using lower doses of each medicinal product to
achieve the same degree of pain relief41.
In the update to a previous Cochrane review
published in 200050, in 2009, Toms et al. evaluat-
ed the efficacy and safety of paracetamol com-
bined with codeine, using recent data41. The
paracetamol-codeine combination provided clini-
cally useful pain relief levels in at least 50% of
patients with moderate-to-severe postoperative
pain, compared to less than 20% in patients re-
ceiving placebo. Moreover, the use of a combina-
tion of the two drugs extends the duration of
analgesia by approximately one hour compared
to the dose of paracetamol alone41.
In a recent review8, the codeine-paracetamol
combination was considered efficacious in the
treatment of various types of pain, thanks to the
synergistic action of the two molecules. Despite
the scientific evidence cannot be considered con-
clusive, due to the non-uniformity of the trials,
some of which were very old, the authors con-
clude in favour of the non-inferiority of the
paracetamol-codeine combination compared with
NSAIDs in the treatment of different types of
pain. They also stressed that NSAIDs have a
greater incidence of potentially harmful side ef-
fects, and suggest using this combination in the
management of moderate-to-severe pain, particu-
larly in elderly patients, in those with severe car-
diovascular risks or in those on primary or sec-
ondary prevention treatment for stroke or acute
coronary syndrome.
Another recent study51 analyzed the effects
of a global rehabilitation programme on 44 pa-
tients with osteoarthritis awaiting total joint re-
placement. The addition of paracetamol to the
rehabilitation programme at the maximum daily
dose of 3 g/day statistically reduces the intensi-
ty of pain. In addition, in case of failure with
paracetamol alone, the authors suggested the
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use of a 500/30 mg paracetamol-codeine com-
bination, as this treatment has been shown to be
particularly efficacious when compared to
paracetamol alone51.
Another group of patients particularly com-
plex to be managed is that of polytrauma vic-
tims, in which it is essential to treat both acute
and chronic pain appropriately. The association
codeine/paracetamol has been shown to be a
valid alternative to NSAIDs, such as ketorolac,
especially in patients with a documented haem-
orrhage or with a high haemorrhagic risk52. In-
deed, although NSAIDs are the agents most fre-
quently used in these patients, their use can be
associated with an increased risk of haemor-
rhage. Italian Intersociety Recommendations on
pain management in the emergency setting sug-
gested to use paracetamol for its opioid sparing
properties and for reduction of opioid related
adverse events. The combination paracetamol-
codeine 500/30 mg, repeatable every 6 hours, is
suggested for moderate pain (numeric rating
scale 4-6)53.
A recent prospective, double-blind clinical tri-
al54 evaluated a cohort of over 170 patients with
acute post-traumatic limb pain, discharged from
the emergency department, randomized to be
treated with a hydrocodone-paracetamol combi-
nation (5 mg/500 mg) or with codeine-paraceta-
mol (30 mg/300 mg). The study outcomes were
improvement in pain two hours after taking one
of the 2 medicinal products, onset of side effects
and the degree of patient satisfaction. Both com-
binations reduced pain by about 50%. The hy-
drocodone-paracetamol combination did not
show any statistically significant superiority in
either the control of pain or overall patient satis-
faction, with similar side effects in both groups.
The authors concluded that this data should en-
courage physicians to give more consideration to
the use of the paracetamol/codeine combination
in this setting of patients with acute pain.
Conclusions
More than a century after its advent, paraceta-
mol remains the most widely-used analgesic
agent. Despite its lengthy history, its beneficial
analgesic and antipyretic effects, as well as its
secondary effects, still represent the subject of a
great number of publications, as the mechanisms
responsible for these effects are still not com-
pletely clear.
A PubMed search showed that there was an in-
crease from just 1 paper indexed in 1957 to
243/year in 1982, i.e. 25 years later, before leap-
ing to 828/year 25 years later in 2007 and 1076
publications/year in 2013.
Recent studies reveal a new approach to
paracetamol: a pro-drug that needs to be bio-
transformed in order to exert its analgesic ef-
fect. Different neurophysiological systems ap-
pear to be involved in the mechanism of action
of paracetamol, from the serotoninergic to the
opioidergic systems, to which we can also add,
based on current knowledge, the cannabinoider-
gic and vanilloidergic system. Paracetamol is
currently recommended as the preferred anal-
gesic in various conditions, as it is considered
safe and efficacious for the management of
mild pain and because it can be used for
lengthy periods of time, even in elderly pa-
tients, in whom the cardiovascular, renal and
gastrointestinal risks associated with the chron-
ic use of NSAIDs is well known.
It has also been shown that in cases of inade-
quate analgesia with paracetamol alone, the use
of formulations constituted by a combination
with a mild opioid such as codeine is effica-
cious. Indeed, thanks to the synergistic action of
the individual active ingredients, this combina-
tion significantly increases the analgesic effect,
without increasing side effects and its ease of
management makes it a good option for the con-
tinued home treatment of post-traumatic or oth-
er acute and chronic pain.
Recent scientific progresses led to subdivide
patients according to their ability to metabolise
codeine, bringing to light the specific analgesic
role of the metabolites of this agent, and not
merely the part that is transformed into mor-
phine.
Therefore, fixed-dose analgesic combinations,
in this case paracetamol/codeine, offer patent ad-
vantages in different types of patients and differ-
ent clinical settings, when molecules with com-
plementary mechanisms of action are chosen,
when the appropriate doses of the single compo-
nents are identified, in order to limit side effects,
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